haematology
Blood cancers

Venetoclax plus azacitidine may be new standard of care for older AML patients

Trial results showing improved overall survival with a combination of azacitidine and venetoclax may prompt a change how clinicians approach treatment in older adults newly diagnosed with acute myeloid leukaemia (AML). Results from the VIALE-A trial presented at the European Hematology Association virtual congress (EHA25) showed that the combination of azacitidine and venetoclax was associated ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic